Nachrichten und Videos - CANDEL THERAPEUTICS INC. - Seite 3

NEEDHAM, Mass., June 08, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced the appointment of Nicoletta Loggia, PhD, RPh, to the Company’s Board of Directors (Board) effective June 7, 2023. “We are pleased to welcome Nicoletta as a new member of Candel’s Board,” said Paul Peter Tak, MD, PhD, FMedSci, President and...

NEEDHAM, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will give a corporate presentation at the upcoming Jefferies Healthcare Conference, taking place June 7 – 9, 2023, in New York City. Format: Corporate Presentation...

Treatment with CAN-3110 in arm A showed encouraging median overall survival rate at 11.8 months after a single injection. These data are supported by independent cohort (arm B); median overall survival was 12.0 months in patients who received a single administration of CAN-3110 after cyclophosphamide pre-treatment compared to < 6 to 9 months expected with standard of care treatment options CAN-3110 was reported to be well tolerated with no dose-limiting toxicities observed The Company is...

NEEDHAM, Mass., May 11, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the first quarter ended March 31, 2023, and provided a corporate update. “In the first quarter, we continued to advance our off-the-shelf investigational viral immunotherapies designed to produce an...

NEEDHAM, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced an abstract detailing new data from its phase 1 clinical trial of CAN-3110 in patients with recurrent high-grade glioma was accepted as an oral presentation in the upcoming American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting in Los...

NEEDHAM, Mass., April 17, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today announced that the U.S. Food and Drug Administration (FDA) granted fast track designation for its lead asset CAN-2409, an investigational viral immunotherapy, plus valacyclovir in combination with pembrolizumab in order to improve survival...

Expects to announce clinical trial data from multiple oncology programs in the second half of 2023 Extends cash runway into second quarter of 2024 NEEDHAM, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and full year ended December 31, 2022 and...

NEEDHAM, Mass., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2023 Healthcare Talks Oncology Day taking place Feb. 8 – 9, 2023, at the St. Regis Hotel in New York City. Details are as follows: Format: Fireside Chat Date/Time: Wednesday,...

NEEDHAM, Mass., Jan. 12, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a virtual fireside chat at B. Riley Securities’ 3rd Annual Oncology Conference. Details are as follows: Format: Virtual Fireside Chat Date/Time: Thursday, January 19, 2023, at 11:30 am EST A live webcast of...

Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved progression-free survival Highlighted effects of a single injection of CAN-3110 in recurrent high-grade glioma (HGG) demonstrating a median overall survival (mOS) of 11.6 months Due to promising clinical activity, portfolio decision made to prioritize CAN-3110 in...

New clinical data to be presented from the Company’s phase 2 clinical trial of CAN-2409 in combination with anti-PD-1 agents in patients with late-stage non-small cell lung cancer. Recent clinical data for CAN-3110 and CAN-2409 in high-grade glioma to be presented. Scientific rationale for the recently announced collaboration with the University of Pennsylvania using Candel’s enLIGHTEN ™ discovery platform to be discussed. Premier experts and thought leaders in immunology and oncology to...

CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissue No dose-limiting toxicities observed in 41 patients with recurrent high-grade glioma (rHGG) Median overall survival was 11.6 months after a single injection of CAN-3110 in patients with rHGG; one patient achieved a complete response lasting more than one year CAN-3110 observed to activate lymphocyte-depleted tumor microenvironment in rHGG, with changes in T cell receptor...

Combination of nivolumab and CAN-2409 delivered during neurosurgery was generally well tolerated with no significant added toxicity compared to standard of care Systemic immune activation was observed in peripheral blood following administration of CAN-2409/valacyclovir prior to nivolumab treatment Median overall survival (mOS) for patients with methylated MGMT promoter was 30.6 months for those undergoing gross total resection (GTR) and 12.6 months for those undergoing sub-total resection...

Discovery collaboration underway with Center for Cellular Immunotherapies Lab at University of Pennsylvania to Study Combinations of Novel Viral Immunotherapy and CAR-T Cell Therapy Candidates in Solid Tumor Models Upcoming clinical data presentations at SITC and SNO Annual Meetings Virtual R&D Day on December 6, 2022, with Candel leadership and renowned oncology experts NEEDHAM, Mass., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical...

Goal of evaluating combination of novel viral immunotherapies with aim to potentiate CAR-T cell therapies in solid tumors Employs Candel’s enLIGHTEN ™ Discovery Platform Both parties retain rights in respective programs and the rights to proceed towards clinical trials to study these combination therapies in patients with solid tumors NEEDHAM, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a clinical stage biopharmaceutical company...

NEEDHAM, Mass., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on the Company’s application for orphan drug designation for CAN-2409 for the treatment of glioma. CAN-2409, a genetically modified adenovirus and the...

Jason A. Amello joins Candel as Chief Financial Officer Garrett Nichols, MD, MS, joins Candel as Chief Medical Officer NEEDHAM, Mass., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL) (Candel or the Company), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Jason A. Amello, has been named as the Company’s Chief Financial Officer (CFO) and Garrett Nichols, MD, MS, has been named as the Company’s...

NEEDHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer will participate in two upcoming investor conferences. Citi's 17th Annual BioPharma Conference Format: Investor meetings Date: Wednesday, September 7 Location: Boston, MA H.C. Wainwright 24th Annual Global Investment...

NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “Candel remains on track to achieve several milestones in the second half of 2022,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief...

Gary Nabel, MD, PhD, Chief Innovation Officer of OPKO Joseph Papa, Chief Executive Officer of Bausch + Lomb Corporation Renee Gaeta, Chief Financial Officer of Eko Devices NEEDHAM, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies, today announced the appointment of three new members to its Board: Gary Nabel, MD,...